Clinical trials: Plasmodium Vivax
Uncomplicated Falciparum Malaria, Vivax Malaria
A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan
Malaria is a major public health problem in many provinces of Afghanistan the failure rate of chloroquine (CQ) and amodiaquine (AQ) treated Plasmodium falciparum(Pf) malaria has risen to more than 60% overall and as high as 90%…
- Trial name
- NCT00682578
- Testing
- Dihydroartemisinin + Piperaquine (Artekin), artesunate-sulphadoxin/pyrimethamine, chloroquine
- Where
- 4 sites in Afghanistan
- Volunteers
- 1,086 people
- Sponsor
- University of Oxford
Advanced Malignant Solid Tumor
Plasmodium Immunotherapy for Advanced Malignant Solid Tumors
The purpose of this study is: 1) to evaluate the effectiveness and extended safety of the Plasmodium immunotherapy for the advanced malignant solid tumors.
- Trial name
- NCT04165590
- Testing
- Plasmodium immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- CAS Lamvac Biotech Co., Ltd.
Malaria, Vivax
Tafenoquine Thorough QTc Study in Healthy Subjects
This will be a randomized, single-blind, placebo controlled, parallel group study. Approximately 260 subjects will be enrolled in five groups.
- Trial name
- NCT01928914
- Testing
- Tafenoquine 300mg, Tafenoquine 600mg, Tafenoquine 1200mg
- Where
- 2 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malaria, Vivax Malaria
Eight Week Primaquine Regimen for the Treatment of Vivax Malaria
Plasmodium vivax represents a major health problem throughout the tropics. Outside Africa it accounts for over 50% of cases, affecting an estimated 70-80 million people per year.
- Trial name
- NCT00158587
- Testing
- primaquine
- Volunteers
- 150 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Plasmodium Falciparum Infection
Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Myanmar
This stepped-wedge cluster-randomized controlled trial with nested mixed methods study will assess the effectiveness, acceptability, feasibility and cost effectiveness of a personal protection package to reduce malaria…
- Trial name
- NCT05025761
- Testing
- Personal protection package
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Malaria
Blood-Stage Plasmodium Vivax Cell Bank
Background: Malaria is caused by a parasite (a type of germ called P. vivax) that is carried by mosquitoes. The disease is transmitted to people when they are bitten by infected mosquitoes.
- Trial name
- NCT05095272
- Testing
- HMPBS02-Pv
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Drug Pharmacokinetics in Healthy Volunteers
Postpartum 8-aminoquinoline Breast Milk Study
In Papua New Guinea, administration of primaquine (PQ) or tafenoquine (TQ) to breastfeeding mothers is contraindicated during the first six months postpartum, when infants are recommended to be exclusively breastfed, because of a…
- Trial name
- NCT07060404
- Testing
- Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water, Daily primaquine 1 mg/kg per day for 7 days given with food and water, Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort
- Where
- Papua New Guinea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Curtin University
Plasmodium Vivax
Phenotyping and Genotyping of Duffy Antigen
Malaria remains the world's leading parasitic endemic. Almost half of the world's population lives in endemic areas. Many at-risk people in African countries remain without access to malaria control.
- Trial name
- DARC (NCT05527119)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
Malaria
A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection
Part A -Cohort 1 DSM265 will be administered as a single dose (400 mg). For cohort 1 only, an additional single dose (400 mg) of DSM265 may be given if gametocytemia develops.
- Trial name
- DSMOZ-2 (NCT02573857)
- Testing
- DSM265, OZ439
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Efficacy, Malaria
Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax
The goal of this open label clinical trial will be to assess the therapeutic efficacy of chloroquine plus primaquine in the treatment of uncomplicated plasmodium vivax in Shecha Health Center, South Ethiopia.
- Conditions
- Efficacy, Malaria, Chloroquine, Vivax Malaria
- Trial name
- CQ+PQ (NCT06044805)
- Testing
- Chloroquine, Primaquine
- Where
- Ethiopia
- Volunteers
- 100 people
- Sponsor
- Dinka Dugassa
Falciparum Malaria, Vivax Malaria
To Evaluate Current Efficacy of Antimalarials Used in Timika, Papua, Indonesia
Multidrug resistant strains of P.falciparum and P.vivax are becoming increasingly prevalent in the Asia Pacific rim. To determine the efficacy of locally recommended antimalarial protocols in Papua, Indonesia, consecutive…
- Trial name
- NCT00157859
- Testing
- Chloroquine and sulphadoxine-pyrimethamine
- Where
- Indonesia
- Volunteers
- 150 people
- Sponsor
- Menzies School of Health Research
Malaria, Vivax
Radical Cure (RC) With Tafenoquine or Primaquine After Semi-quantitative G6PD Testing: A Feasibility Study in Peru
The goal of this study is to evaluate the operational feasibility of using a new treatment algorithm for Malaria Vivax in Peru. The implementation package includes the following interventions: A revised vivax treatment algorithm…
- Trial name
- NCT05361486
- Testing
- Tafenoquine (TQ)
- Where
- Peru
- Volunteers
- 187 people
- Sponsor
- Medicines for Malaria Venture
Malaria
Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites
It is possible to safely protect human volunteers immunized with P. vivax irradiated sporozoites from P. vivax challenge with live sporozoites.
- Trial name
- SPZ-Irrad (NCT01082341)
- Testing
- Immunization with P. vivax irradiated sporozoites
- Where
- Colombia
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Malaria Vaccine and Drug Development Center
Vivax Malaria, Plasmodium Vivax
Effectiveness of Novel Approaches to Radical Cure With Tafenoquine and Primaquine
Health care facility based, randomized, controlled, open label, superiority trial with 3 arms
- Conditions
- Vivax Malaria, Plasmodium Vivax, Malaria, Vivax, Malaria Relapse
- Trial name
- EFFORT (NCT04411836)
- Testing
- Tafenoquine, Primaquine
- Where
- 6 sites in Cambodia, Ethiopia and 2 more
- Volunteers
- 960 people
- Sponsor
- Menzies School of Health Research
Plasmodium Falciparum and Plasmodium Vivax
Malaria Genetic Surveillance
This study is to determine the prevalence and geographical distribution of antimalarial drug resistance-linked genetic mutations in clinical P. falciparum and/or P.Vivax infection in the Greater Mekong Subregion
- Trial name
- NCT03384498
- Where
- 3 sites in Cambodia, Laos and 1 more
- Volunteers
- 30,000 people
- Sponsor
- University of Oxford
Malaria, Mass Drug Administration
Efficacy of Focal Primaquine Mass Administration for Eliminating Plasmodium Vivax Malaria in Northern Myanmar
Plasmodium vivax has become the predominant species in the Greater Mekong Subregion and is a major challenge for regional malaria elimination.
- Conditions
- Malaria, Mass Drug Administration, Myanmar, Plasmodium Vivax
- Trial name
- NCT06392152
- Testing
- Focal Mass Drug Administration with Primaquine
- Where
- Burma
- Volunteers
- 1,208 people, healthy volunteers welcome
- Sponsor
- Pyae Linn Aung
Malaria, Malaria Vivax
This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly Acting Anti-malarial for the Radical Cure of P. Vivax Malaria
The goal of this Phase 2b study is to examine the safety and efficacy of the combination of SJ733, an investigational agent, and tafenoquine for the radical cure of uncomplicated P.
- Conditions
- Malaria, Malaria Vivax, Radical Cure
- Trial name
- SJ733-2002 (NCT07430592)
- Testing
- CQ/TQ, SJ733 (3-day)/TQ, SJ733 (2-day ) /TQ
- Where
- Peru
- Volunteers
- 104 people
- Sponsor
- R. Kiplin Guy
Uncomplicated Vivax Malaria
IMPROV (Improving the Radical Cure of Vivax Malaria)
The main determinant of primaquine efficacy is the total dose of primaquine administered, rather than the dosing schedule. Previous trials have demonstrated that the standard low dose regimen of primaquine (3.5 mg/kg total) fails…
- Trial name
- NCT01814683
- Testing
- Primaquine
- Where
- 8 sites in Afghanistan, Ethiopia and 2 more
- Volunteers
- 2,388 people
- Sponsor
- University of Oxford
Plasmodium Vivax Infection, Malaria Vaccine
A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 )
This project is the third part of a 5-year research program entitled "Malaria Infection Studies in Thailand (MIST)" and known as MIST3.
- Trial name
- MIST3 (NCT05380388)
- Testing
- Malaria Vaccine, HBV vaccine
- Where
- Thailand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Plasmodium Vivax Infection
A Controlled Human Vivax Malaria Infection Study Through Inoculation of Infected Erythrocytes
The primary objectives of this study are to assess the safety and feasibility of blood-stage controlled human P. vivax malaria infection (CHMI) in healthy adult Thai volunteers through experimental injection of cryopreserved P.
- Trial name
- MIST2 (NCT05071079)
- Testing
- An inoculum of malaria parasitised red blood cells with whole dose blood-stage inoculum, An inoculum of malaria parasitised red blood cells with 1:5 dilution blood-stage inoculum, An inoculum of malaria parasitised red blood cells with 1:10 dilution blood-stage inoculum
- Where
- Thailand
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Oxford